In indications with a neutral or positive effect of Ep-CAM overexpression on survival, the high proportion of Ep-CAM positive cells in tumours may still be efficacious in particular if the targeted immunotherapy is combined with chemotherapeutics, and if used in adjuvant settings as are characterised by low tumour load. Here, EPCAM is linked to neoplasm.